Efgartigimod

Phase 3

argenx SE (ARGX)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

10mo

ARGXPDUFA$50.3B

Phase 3

FDA PDUFA Date efgartigimod alfa-fcab (priority)

Efgartigimod• Postural Orthostatic Tachycardia Syndrome

Jan 3Confirmed

SEC

00%

3mo

ARGXPDUFA$50.3B

Phase 3✅Approved

FDA PDUFA Date efgartigimod (priority)

Efgartigimod• Postural Orthostatic Tachycardia Syndrome

Jun 7Confirmed

SEC

Development History

Past

days

ARGXPhase 3$50.3B

✓Positive

efgartigimod Phase 3 Results Expected

Efgartigimod• Postural Orthostatic Tachycardia Syndrome101

Mar 11Estimated

CT.gov

Competitive Landscape

0 competitors in Postural Orthostatic Tachycardia Syndrome

View Full Landscape

Drug Information

Target Indication

Postural Orthostatic Tachycardia Syndrome

Clinical Trial

NCT05633407

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ARGX

argenx SE

Biological Products, (No Diagnostic Substances)•Europe•NASDAQ

Related Pipeline

ARGX-113Phase 3

Pemphigus Vulgaris

Efgartigimod PH20 SCPhase 3

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

EFG PH20 SCPhase 3

Active Idiopathic Inflammatory Myopathy

IVIG (Intravenous Immunoglobulin)Phase 3

Multifocal Motor Neuropathy (MMN)

Efgartigimod IVPhase 3

Generalized Myasthenia Gravis

View full pipeline